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ABBREVIATION AND ACRONYMS 
 
CT = computed tomography 
MAC = Mitral annular calcification 
MIP = maximal intensity projection 
MR = mitral regurgitation 
MRI = magnetic resonance imaging 
MS = mitral stenosis 
MVA = mitral valve area 
MVD = mitral valve disease 
STS = Society of Thoracic Surgeons 
TAVR = transcatheter aortic valve replacement 
VARC = Valve Academic Research Consortium 
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Introduction 
 Severe mitral annular calcification (MAC) has a prevalence of 9 to 18% in patients undergoing 
transcatheter aortic valve replacement (TAVR) and has been independently associated with increased 
mortality (1, 2). MAC often coexists with, or results in mitral regurgitation (MR) or mitral stenosis (MS) 
(1, 3-8). However, MAC has largely been studied in isolation from functional parameters of mitral 
valve disease (MVD), which themselves confer an increased risk of death (9-13). MAC has been 
demonstrated in a majority of TAVR patients with moderate or severe mitral stenosis (12).  
 We therefore aimed to assess the impact of MAC with and without significant MVD on clinical 
outcomes in patients undergoing TAVR, integrating both functional and anatomical assessments of 
the mitral valve apparatus using an integrated analysis of echocardiography and computed 
tomography (CT). 
 
Methods 
Study population 
 All patients undergoing TAVR at Bern University Hospital, Bern, Switzerland, are consecutively 
enrolled into a prospective institutional registry that is a part of the Swiss TAVI registry 
(NCT01368250). Patients were excluded if a non-CE marked device was used or if no transcatheter 
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heart valve was implanted. The registry was approved by the local ethics committee, and patients 
provided written informed consent to participate. For the purpose of the present study, only patients 
without prior mitral valve surgery were considered. Furthermore, patients without pre-procedural 
echocardiographic and CT raw data adequate for a reliable assessment of the mitral valve apparatus 
were excluded from the present analysis. 
Assessment of mitral annular calcification 
 MAC was assessed by CT, which is a validated modality to predict the extent and location of MAC and 
assess its severity (14). The ECG-gated multi-slice CT was performed on either a Siemens Somatom 
Sensation Cardiac 64 scanner with a slice collimation of 64 x 0.75mm or a Siemens Somatom 
Definition Flash Dual-Source scanner with a slice collimation of 128 x 0.6 mm, tube voltage of 100 or 
120 kV, and tube current according to patient size (Siemens Medical Solutions, Inc., Forchheim, 
Germany). Each patient received an intravenous injection of 80-120 mL of contrast medium at a flow 
rate of 5 mL/s and image acquisition was performed during an inspiratory breath-hold in a cranio-
caudal direction. Acquired CT images were transferred to a dedicated workstation (3mensio 
Structural Heart, 3mensio Medical Imaging BV, Bilthoven, The Netherlands) in the Corelab and re-
evaluated by independent investigators blinded to clinical outcomes. Several views including axial and 
double oblique views at the mitral annular level as well as a maximal intensity projection (MIP) 
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reconstruction were used to assess the presence of MAC and its severity. MAC was defined as 
calcification located at the junction between the left atrium and left ventricle. MAC severity was 
qualitatively determined by the circumferential involvement of the mitral ring: mild was defined as 
involvement in less than 1/3 of the annulus; moderate between 1/3 and 1/2; and severe if the 
calcification was present in more than half of the mitral annulus circumference (Figure 1) (1, 15). 
Assessment of mitral valve disease 
 The assessment of MVD was performed by echocardiography as previously described (11, 12). Briefly, 
transthoracic and/or transesophageal echocardiography were performed by a board-certified 
cardiologist with a Philips iE33 machine (Philips Healthcare, Andover, MA, USA). Acquired images 
were transferred to a dedicated workstation (Syngo Dynamics Workplace, version 9.5, Siemens 
Medical Solustions, Inc, PA, USA) in the Corelab and re-evaluated by independent investigators 
blinded to clinical outcome. The degree of MR and MS was assessed at baseline using structural, 
spectral, and color-Doppler images and were graded as mild, moderate, and severe using multi-
parametric assessments according to the European Association of Echocardiography/American 
Society of Echocardiography recommendations (16, 17). In the present study, significant MVD was 
considered in the presence of at least moderate mitral regurgitation or mild or greater mitral stenosis. 
The rationale for this categorization was that these respective grades have been associated with an 
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increased risk of mortality in patients undergoing TAVR (9-13). 
Transcatheter aortic valve replacement 
 The optimal therapeutic strategy in each patient was based on a heart team decision. Presence or 
absence of MVD regularly affected decision-making on the optimal treatment strategy. In contrast, 
isolated MAC was rarely taken into consideration during the heart team discussion. MAC was however 
taken into account in combination with MVD for the assessment of anatomical and technical 
suitability of mitral valve surgery or transcatheter intervention. TAVR was performed via transfemoral 
access by default. A trans-apical or trans-subclavian approach was used in patients with inadequate 
peripheral access. Post-procedural care included rhythm monitoring for at least 48h after the 
intervention, laboratory testing, and daily 12-lead electrocardiograms until discharge.  
Data collection and clinical follow-up 
 Baseline clinical data, procedural characteristics, and follow-up data were entered into a dedicated 
database, held and maintained by the Clinical Trials Unit of the University of Bern. Clinical follow-up 
data at 30 days and 1 year were obtained by standardized interviews, documentation from referring 
physicians, and hospital discharge summaries. All adverse events were systematically collected and 
adjudicated by a dedicated clinical event committee according to the Valve Academic Research 
Consortium (VARC-2) criteria (18). The pre-specified primary endpoint of the present study was all-
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cause death at 1 year after TAVR. Secondary endpoints included cardiovascular death and disabling 
stroke at 1 year, all-cause death, cardiovascular death, myocardial infarction, disabling stroke, major 
or life-threatening bleeding, major vascular complication, kidney injury (stage 3), and permanent 
pacemaker implantation at 30 days after TAVR. Composite outcome of all-cause death and disabling 
stroke at 30 days and 1 year after TAVR are also described. 
Statistical analysis 
 Categorical data are represented as frequencies and percentages and the differences between 
groups are evaluated with the Chi-square test or Fisher’s exact test. Continuous variables are 
expressed as mean values ± standard deviation (SD) and compared between groups using F test. 
Event-free survival curves were constructed using the Kaplan-Meier method. Univariate unadjusted 
Cox proportional hazards model was used to calculate crude hazard ratios (HR) and 95% confidence 
intervals (95% CI) for the clinical outcomes. Multivariable Cox regression was performed to identify 
independent predictors of all-cause death. All the variables were stepwise tested for entry into the 
multivariate model, with p-value of <0.10. The adjusted Cox proportional hazards model estimates 
were based on 20 multiple imputed datasets, combining estimates using Rubin’s rule, adjusting for 
body mass index, NYHA class Ⅲ or Ⅳ, diabetes, prior stroke or transient ischemic attack, peripheral 
artery disease. Throughout the present study, a p-value of <0.05 was considered significant. Statistical 
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analyses were performed using Stata 15.1 (StataCorp, College Station, TX, USA). 
 
Results 
 Among 1811 consecutive patients undergoing TAVR between August 2007 and June 2017, a total of 
967 individuals met the inclusion criteria and were considered for the purpose of the present analysis. 
At one year, outcomes were known from 960 patients (99.3%), 6 patients refused follow-up and 1 
patient was not traceable.  MAC was found in 609 patients (63.0%) and considered mild or moderate 
in 437 (45.2%) and severe in 172 (17.8%) (Figure 2). A total of 87 patients (50.6%) with severe MAC 
had relevant MVD compared to 228 patients (28.7%) with non-severe MAC (p<0.001) (Figure 3).  
Baseline and procedural characteristics 
 The baseline characteristics of the study population are summarized in Table 1,2. Patients with 
severe MAC were more frequently female. Patients with MVD or severe MAC had a higher estimated 
risk as assessed by the Society of Thoracic Surgeons (STS) risk score. 
Overall, transfemoral access was used in 90.6% of the cases and 22.3% of the cases were performed 
under general anesthesia. The rate of periprocedural complications were comparable across groups 
and are shown in Table 3. 
Clinical outcomes 
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 Survival curves according to severity of MAC are shown in Figure 4. Neither patients with severe MAC 
nor patients with mild or moderate MAC had an increased risk of all-cause [HR: 0.92, 95% CI: 0.56-
1.53; HR: 0.87, 95% CI: 0.59-1.28; respectively] or cardiovascular death [HR: 1.22, 95% CI: 0.69-2.15; 
HR: 0.78, 95% CI: 0.47-1.28; respectively] as compared to patients without MAC. 
 Clinical outcomes at 30 days and 1 year stratified by presence or absence of severe MAC and relevant 
MVD are summarized in Table 4,5. Compared to patients without severe MAC and MVD, patients with 
isolated MVD had increased risks of all-cause [6.6% vs. 2.1%, HR: 3.16, 95% CI: 1.48-6.75] and 
cardiovascular death [6.2% vs. 1.8%, HR: 3.54, 95% CI: 1.57-7.96] at 30 days. Patients with severe 
MAC in combination with MVD had numerically higher risks of all-cause death [5.7% vs. 2.1%, HR: 
2.73, 95% CI: 0.96-7.76] and cardiovascular death [4.6% vs. 1.8%, HR: 2.63, 95% CI: 0.82-8.37] at 30 
days. Both patients with isolated MVD and patients with severe MAC in combination with MVD had 
an increased risk of bleeding compared to patients without severe MAC and MVD [30.4% vs 23.7%, 
HR: 1.31, 95% CI: 0.98-1.75; 39.3% vs. 23.7%, HR: 1.72, 95% CI: 1.18-2.50; respectively]. Patients with 
severe MAC in combination with MVD had a numerically higher risk of atrioventricular conductance 
disturbances and need for permanent pacemaker implantation as compared to patients without 
severe MAC and MVD [27.9% vs. 20.1%, HR: 1.48, 95% CI: 0.95-2.29]. 
 At 1 year, both patients with isolated MVD and patients with severe MAC in combination with MVD 
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had increased risks of all-cause death [23.4% vs. 8.8%, HR: 2.89, 95% CI: 1.96-4.26; 19.5% vs. 8.8%, 
HR: 2.40, 95% CI: 1.38-4.17; respectively] and cardiovascular death [15.8% vs. 5.1%, HR: 3.32, 95% CI: 
2.02-5.45; 17.5% vs. 5.1%, HR: 3.69, 95% CI: 1.97-6.90; respectively], while patients with isolated 
severe MAC did not have an increased risk of all-cause death [6.0% vs. 8.8%, HR: 0.67, 95% CI: 0.27-
1.67] or cardiovascular death [4.8% vs. 5.1%, HR: 0.93, 95% CI: 0.33-2.66] as compared to patients 
without severe MAC and MVD (Figure 5).  
The incremental risk of concomitant MVD on mortality in patients undergoing TAVR is summarized in 
Figure 6.  
 In a multivariate analysis, both isolated MVD and severe MAC concomitant with MVD emerged as 
independent predictors of all-cause death at 1 year [HRadj: 2.33, 95% CI: 1.56-3.47; HRadj: 1.97, 95% 
CI: 1.12-3.44; respectively] (Table 6). Multivariate Cox regression analysis was also performed to 
evaluate the independent effects of severe MAC, significant MS, and MR on 1-year mortality. As 
shown in Table 7, significant MS and MR were both independent predictors of all-cause death [HRadj: 
2.37, 95% CI: 1.53-3.66; HRadj: 1.88, 95% CI: 1.20-2.94; respectively], whereas severe MAC was not 
[HRadj: 1.16, 95% CI: 0.69-1.96].  
Association between the severity of MAC and the prevalence of MVD 
 Prevalence and severity of MS and MR according to severity of MAC are summarized in Figure 7. The 
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prevalence of mild or greater MS gradually increased with incremental severity of MAC with 
significant correlation (Spearman’s rho=0.185, p<0.001). Although the prevalence of moderate or 
severe MR was the highest in patients with severe MAC, there was no significant correlation 
(Spearman’s rho = 0.034, p=0.295). 
 
Discussion 
 The main findings of the present study can be summarized as follows. 1) Patients with severe MAC 
had comparable survival throughout one year of follow-up compared to patients with non-severe 
MAC. 2) More than half of all patients with severe MAC had relevant MVD, which was significantly 
higher than patients with non-severe MAC. 3) Patients with severe MAC and coexisting MVD had an 
increased risk of all-cause and cardiovascular death at 30 days and 1 year, whereas patients with 
isolated severe MAC without MVD had comparable survival to patients without severe MAC and MVD.  
MAC prevalence increases with both age, co-existent renal impairment and cardiovascular risk 
suggesting an association to the pathogenesis of atherosclerosis. It has similarities with the 
development of calcific aortic stenosis in that foci of endothelial injury at sites of mechanical stress 
result in an inflammatory response with macrophage and T-cell infiltrates, encouraging the expression 
of bone morphogenetic proteins from myofibroblasts and preosteoblasts adjacent to these 
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lymphocytic infiltrates contributing to calcification (19). 
There is limited evidence that MAC is associated with an increased prevalence of MR and MS (3-6). 
In the study by Abramowitz et al., baseline MR distribution was similar between patients with and 
without MAC, however, in severe MAC alone, severe MR was frequently observed. Although baseline 
MS distribution was not described in detail, baseline mitral valve mean gradients were significantly 
higher in patients with severe MAC (1). In our current analysis, the prevalence and severity of MS 
were significantly correlated with the CT-assessed MAC severity. Moreover, the prevalence was 
apparently higher in patients with severe MAC even in comparison with mild or moderate MAC. 
Although the correlation between MAC severity and MR was not statistically significant, the 
prevalence of moderate or severe MR was also the highest in patients with severe MAC. Consequently, 
increased prevalence of MVD was observed in patients with severe MAC but not in patients with mild 
or moderate MAC. This finding suggests that severe MAC might have a greater impact on mitral valve 
function. 
Previously, MAC has been identified as a risk factor for increased mortality in patients undergoing 
TAVR as well as in other populations (1, 2, 20-22). However, the association of MAC with mortality 
has typically been studied in isolation from concomitant MVD (2, 20, 21). Although Abramowitz et al. 
reported similar prevalence of MR and increased mitral valve mean gradients in patients with severe 
Published in final edited form as: Eur Heart J Cardiovasc Imaging. 2019 Aug 13. pii: jez208. doi: 10.1093/ehjci/jez208 
14 
 
MAC, the multivariate analysis included neither MR nor mitral valve mean gradient (1). Ramaraj et al. 
identified MAC as an independent predictor of all-cause death in a retrospective analysis of 3169 
clinical echocardiograms. Although the multivariate analysis included significant valvular 
abnormalities, independent prevalence and additional effects on mortality of MR and MS were not 
analyzed (22). To the best of our knowledge, this study is the first to investigate the prognostic impact 
of MAC on TAVR in relation to systematically assessed MVD.  
In contrast to previous reports (1, 2), we did not document an association of severe MAC with 
increased mortality. The present study demonstrated that severe MAC was not an independent 
predictor of mortality in patients undergoing TAVR, whereas concomitant MR and MS were both 
independent predictors. MAC represents chronic calcification of fibrous tissue surrounding the mitral 
valve and in most cases has little impact on mitral valve function. In advanced cases, the excessive 
calcification may freeze normal annular dynamics or encroach upon the leaflet bodies and mitral 
chordae, reducing leaflet mobility and ultimately causing MS or MR (14). Therefore, MAC itself does 
not have a prognostic impact but is associated with mortality after TAVR if it affects mitral valve 
function significantly. A detailed assessment of concomitant MVD may be an avenue for MVD 
intervention and  improvement of survival in patients with severe MAC. 
The comprehensive assessment of MVD can be challenging because hemodynamic effects of the 
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different valves are interrelated, and the presence of MAC may add further complexity. While 
concomitant AS accentuates MR severity due to increased afterload, MS tends to be underestimated 
by a low-flow low-gradient state with a prolonged pressure half-time caused by impaired left 
ventricular relaxation. Therefore, anatomical assessment including planimetry is deemed important 
in these patients. However, the presence of MAC may complicate planimetric assessment by acoustic 
shadowing and blooming artifacts of the calcification. Recently, the usefulness of CT and magnetic 
resonance imaging (MRI) for the assessment of MVD has been recognized (23-26). The Integrated 
approach of echocardiography and CT or MRI for the comprehensive assessment of the mitral valve 
apparatus including MAC may be of particular importance in patients with AS, since it may affect the 
decision on the optimal treatment strategy. 
Study Limitations 
 Our results should be interpreted in light of several limitations. Firstly, only patients with adequate 
echocardiographic and computed tomographic raw data for a comprehensive assessment of the 
mitral valve apparatus were considered for the purpose of the present analysis. Therefore, 
unintended selection bias might exist in the present study. Secondly, potential confounders might 
exist and statistical techniques might not be sufficient to adjust these factors. Thirdly, there is no 
validated classification for the assessment of MAC on CT. Therefore, we used the qualitative 
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classification of MAC suggested by Abramowitz et al. (1). Further studies are needed to investigate 
the optimal method for the assessment of MAC on CT.  On the other hand, we have several strengths 
in the present study as compared to the previous studies. The present study was based on a 
considerably larger number of patients compared to previous reports. Also the present analysis was 
performed using a rigorous registry database with standardized follow-up and independent event 
adjudication. Finally, the echocardiographic and computed tomographic raw data were re-evaluated 
by independent second readers for the purpose of the study.  
 
Conclusion 
 Isolated severe MAC is not an independent predictor of mortality after TAVR. Severe MAC is however 
associated with a significantly higher incidence of MVD, especially of MS. Significant MVD is 
associated with increased 1 year mortality. Risk evaluation in patients undergoing TAVR and coexisting 
MAC needs to integrate functional assessment of the mitral valve apparatus. 
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Tables 
Table 1. Comparison of Baseline Characteristics 
 No/Non-severe MAC (n=795) Severe MAC (n=172) P=value 
No-MVD 
(n=567) 
MVD 
(n=228) 
No-MVD 
(n=85) 
MVD 
(n=87) 
Age (years) 81.8 ± 6.4 82.3 ± 6.3 83.1 ± 4.7 83.4 ± 6.6 0.056 
Female (n, %) 266 (46.9%) 118 (51.8%) 57 (67.1%) 70 (80.5%) <0.001 
Body mass index (kg/m2)  26.7 ± 5.0 25.3 ± 5.1 26.7 ± 5.0 26.0 ± 5.5 0.006 
STS score: mortality (%) 5.0 ± 3.2 6.5 ± 4.9 5.8 ± 3.4 5.8 ± 3.0 <0.001 
NYHA class Ⅲ/Ⅳ (n, %) 380 (67.0%) 169 (74.4%) 57 (67.1%) 63 (72.4%) 0.186 
Concomitant diseases 
 Hypertension (n, %) 480 (84.7%) 182 (79.8%) 74 (87.1%) 68 (78.2%) 0.159 
 Diabetes (n, %) 129 (22.8%) 51 (22.4%) 27 (31.8%) 23 (26.4%) 0.271 
 Dyslipidemia (n, %) 389 (68.6%) 132 (57.9%) 58 (68.2%) 43 (49.4%) 0.001 
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 CKD (eGFR<60) (n, %) 367 (64.7%) 166 (72.8%) 61 (71.8%) 63 (72.4%) 0.088 
 COPD (n, %) 76 (13.4%) 30 (13.2%) 8 (9.4%) 8 (9.2%) 0.550 
Previous history 
 Coronary artery disease (n, %) 353 (62.3%) 145 (63.6%) 56 (65.9%) 44 (50.6%) 0.132 
 Prior stroke or TIA (n, %) 59 (10.4%) 33 (14.5%) 11 (12.9%) 17 (19.5%) 0.069 
 Peripheral artery disease (n, %) 66 (11.6%) 35 (15.4%) 20 (23.5%) 8 (9.2%) 0.011 
 Atrial fibrillation (n, %) 135 (23.8%) 76 (33.3%) 24 (28.2%) 22 (25.3%) 0.051 
 Permanent pacemaker (n, %) 46 (8.1%) 27 (11.8%) 4 (4.7%) 9 (10.3%) 0.176 
Laboratory data 
 Hemoglobin (g/L) 123.8 ± 17.0 120.6 ± 16.8 121.3 ± 16.7 119.5 ± 13.8 0.020 
 BNP (pg/mL) 488.6 ± 681.8 769.7 ± 950.2 581.8 ± 699.5 776.8 ± 1050.8 <0.001 
Medications 
 Aspirin (n, %) 488 (87.3%) 178 (80.9%) 71 (83.5%) 73 (85.9%) 0.144 
 Clopidogrel (n, %) 410 (73.3%) 157 (71.4%) 65 (76.5%) 62 (72.9%) 0.838 
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 Oral anticoagulation (n, %) 168 (30.1%) 82 (37.3%) 26 (30.6%) 24 (28.2%) 0.223 
 
MAC = mitral annular calcification; MVD = mitral valve diseases including mitral stenosis (≥mild) and mitral regurgitation (≥moderate) ; STS = Society of Thoracic 
Surgeons; NYHA = New York Heart Association; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; TIA = transient ischemic attack. 
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Table 2. Comparison of Echocardiographic and Computed tomographic Data 
 No/Non-severe MAC (n=795) Severe MAC (n=172) P=value 
No-MVD 
(n=567) 
MVD 
(n=228) 
No-MVD 
(n=85) 
MVD 
(n=87) 
Echocardiographic data 
 Aortic valve area (cm2) 0.68 ± 0.24 0.65 ± 0.27 0.62 ± 0.21 0.58 ± 0.23 0.003 
 LV ejection fraction (%) 56.0 ± 13.5 49.1 ± 16.3 59.2 ± 12.4 56.8 ± 12.8 <0.001 
 AR ≥ moderate (n, %) 10 (1.8%) 5 (2.2%) 0 (0.0%) 0 (0.0%) 0.322 
 MR ≥ moderate (n, %) 0 (0.0%) 131 (57.5%) 0 (0.0%) 36 (41.4%) <0.001 
 TR ≥ moderate (n, %) 41 (7.3%) 62 (27.3%) 3 (3.6%) 19 (21.8%) <0.001 
 Severity of MS (n, %)  <0.001 
   Mild 0 (0.0%) 98 (43.0%) 0 (0.0%) 49 (56.3%) 
    Moderate 0 (0.0%) 11 (4.8%) 0 (0.0%) 8 (17.3%) 
   Severe 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (1.1%) 
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 Mitral valve mean gradient 
(mmHg) 
1.42 ± 0.88 2.26 ± 1.92 2.85 ± 1.64 3.99 ± 2.37 <0.001 
Computed tomography data 
 Annulus area (mm2) 460.9 ± 89.2 450.1 ± 77.8 435.2 ± 82.2 419.2 ± 72.0 <0.001 
 AVC calcium (mm2) 325.7 ± 384.5 382.7 ± 416.1 356.1 ± 320.2 383.3 ± 346.6 0.218 
 LVOT calcium (mm2) 12.9 ± 42.1 22.2 ± 71.6 24.7 ± 53.5 36.4 ± 75.1 0.001 
 
MAC = mitral annular calcification; MVD = mitral valve diseases including mitral stenosis (≥mild) and mitral regurgitation (≥moderate) ; LV = left ventricular; LA = 
left atrium; AR = aortic regurgitation; MR = mitral regurgitation; MS = mitral stenosis; AVC = aortic valve complex; LVOT = left ventricular outflow tract. 
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Table 3. Procedural characteristics and complications 
 No/Non-severe MAC (n=795) Severe MAC (n=172) P=value 
No-MVD 
(n=567) 
MVD 
(n=228) 
No-MVD 
(n=85) 
With MVD 
(n=87) 
Fluoroscopy time (min) 19.8 ± 15.2 20.1 ± 8.7 18.7 ± 9.6 20.1 ± 10.9 0.955 
General Anesthesia (n, %) 110 (19.4%) 69 (30.3%) 19 (22.4%) 18 (20.7%) 0.011 
Trans-femoral access (n, %) 523 (92.2%) 197 (86.4%) 75 (88.2%) 81 (93.1%) 0.053 
Type of valve (n, %) 
Balloon-expandable 262 (46.5%) 102 (44.7%) 34 (40.0%) 39 (44.8%) 0.728 
Self-expandable 252 (44.7%) 115 (50.4%) 38 (44.7%) 41 (47.1%) 0.517 
Mechanically expandable 50 (8.9%) 11 (4.8%) 13 (15.3%) 7 (8.0%) 0.027 
Implanted valve size 0.162 
≤27mm 367 (65.1%) 149 (65.4%) 61 (71.8%) 66 (75.9%) 
 
>27mm 197 (34.9%) 79 (34.6%) 24 (28.2%) 21 (24.1%) 
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Pre-dilatation (n, %) 402 (70.9%) 168 (73.7%) 66 (77.6%) 74 (85.1%) 0.034 
Post-dilatation (n, %) 154 (27.2%) 69 (30.3%) 26 (30.6%) 20 (23.0%) 0.545 
Procedural Complications 
 Valve in series (n, %) 9 (1.6%) 3 (1.3%) 2 (2.4%) 1 (1.1%) 0.911 
 Valve dislocation/embolization 
 (n, %) 
15 (3.0%) 2 (1.2%) 1 (1.4%) 3 (4.2%) 0.433 
 Annulus rupture/aortic 
 dissection 
 (n, %) 
3 (0.6%) 4 (2.4%) 0 (0.0%) 1 (1.4%) 0.173 
 Coronary artery occlusion (n, %) 7 (1.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.221 
 
MAC = mitral annular calcification; MVD = mitral valve diseases including mitral stenosis (≥mild) and mitral regurgitation (≥moderate). 
  
Published in final edited form as: Eur Heart J Cardiovasc Imaging. 2019 Aug 13. pii: jez208. doi: 10.1093/ehjci/jez208 
30 
 
Table 4. 30-days Clinical Outcomes 
 No/No-severe MAC 
(n=795) 
Severe MAC 
(n=172) 
No/No-severe MAC 
with MVD* 
Severe MAC with  No-
MVD* 
Severe MAC with 
MVD* 
No-MVD 
(n=567) 
MVD 
(n=228) 
No-MVD 
(n=85) 
MVD 
(n=87) 
HR (95% CI) p 
value 
HR (95% CI) p 
value 
HR (95% CI) p 
value 
 Composite outcome 
 (death/disabling stroke) 
16 (2.8) 20 (8.8) 2 (2.4) 6 (6.9) 
3.17 
(1.64-6.11) 
0.001 
0.82 
(0.19-3.59) 
0.797 
2.47 
(0.97-6.31) 
0.059 
 All-cause death  
12 (2.1) 15 (6.6) 1 (1.2) 5 (5.7) 
3.16 
(1.48-6.75) 
0.003 
0.55 
(0.07-4.23) 
0.566 
2.73 
(0.96-7.76) 
0.059 
  Cardiovascular death 
10 (1.8) 14 (6.2) 1 (1.2) 4 (4.6) 
3.54 
(1.57-7.96) 
0.002 
0.66 
(0.08-5.16) 
0.693 
2.63 
(0.82-8.37) 
0.103 
 Myocardial infarction  
7 (1.2) 3 (1.4) 1 (1.2) 0 (0.0) 
1.07 
(0.28-4.13) 
0.924 
0.95 
(0.12-7.72) 
0.962   
 Disabling stroke  9 (1.6) 7 (3.1) 1 (1.2) 4 (4.7) 1.96 0.181 0.73 0.769 2.92 0.075 
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(0.73-5.27) (0.09-5.79) (0.90-9.47) 
 Bleeding (Any) 
134 (23.7) 69 (30.4) 26 (30.6) 34 (39.3) 
1.31 
(0.98-1.75) 
0.071 
1.33 
(0.87-2.02) 
0.183 
1.72 
(1.18-2.50) 
0.005 
Life-threatening 
34 (6.0) 25 (11.0) 5 (5.9) 6 (6.9) 
1.85 
(1.10-3.10) 
0.020 
0.98 
(0.38-2.51) 
0.968 
1.16 
(0.49-2.76) 
0.742 
Major 
62 (11.0) 32 (14.1) 14 (16.5) 19 (22.0) 
1.30 
(0.85-2.00) 
0.225 
1.52 
(0.85-2.72) 
0.155 
2.04 
(1.22-3.41) 
0.007 
 Vascular complication 
 (Major) 
56 (9.9) 21 (9.3) 9 (10.6) 13 (15.0) 
0.93 
(0.56-1.54) 
0.783 
1.07 
(0.53-2.17) 
0.848 
1.52 
(0.83-2.78) 
0.173 
Kidney injury stage 3 
10 (1.8) 6 (2.7) 3 (3.5) 0 (0.0) 
1.50 
(0.55-4.13) 
0.433 
1.99 
(0.55-7.22) 
0.297   
Pacemaker implantation  
113 (20.1) 45 (20.2) 14 (16.5) 24 (27.9) 
1.02 
(0.72-1.44) 
0.915 
0.81 
(0.47-1.41) 
0.461 
1.48 
(0.95-2.29) 
0.083 
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*Tested versus the reference group, which is no/non-severe MAC with no-MVD. 
HR = hazard ratio; CI = confidence interval; MAC = mitral annular calcification; MVD = mitral valve diseases including mitral stenosis (≥mild) and mitral regurgitation (≥moderate). 
 
  
Published in final edited form as: Eur Heart J Cardiovasc Imaging. 2019 Aug 13. pii: jez208. doi: 10.1093/ehjci/jez208 
33 
 
Table 5. 1-year Clinical Outcomes 
 No/No-severe MAC 
(n=795) 
Severe MAC 
(n=172) 
No/No-severe MAC 
with MVD* 
Severe MAC with  No-
MVD* 
Severe MAC with 
MVD* 
No-MVD 
(n=567) 
MVD 
(n=228) 
No-MVD 
(n=85) 
MVD 
(n=87) 
HR (95% CI) p 
value 
HR (95% CI) p 
value 
HR (95% CI) p 
value 
 Composite outcome 
 (death/disabling stroke) 
59 (10.5) 58 (25.6) 9 (10.7) 18 (20.7) 
2.64 
(1.84-3.79) 
<0.001 
1.01 
(0.50-2.03) 
0.987 
2.11 
(1.24-3.57) 
0.006 
 All-cause death 
49 (8.8) 53 (23.4) 5 (6.0) 17 (19.5) 
2.89 
(1.96-4.26) 
<0.001 
0.67 
(0.27-1.67) 
0.386 
2.40 
(1.38-4.17) 
0.002 
 Cardiovascular death 
28 (5.1) 35 (15.8) 4 (4.8) 15 (17.5) 
3.32 
(2.02-5.45) 
<0.001 
0.93 
(0.33-2.66) 
0.898 
3.69 
(1.97-6.90) 
<0.001 
 Disabling stroke 
16 (2.9) 8 (3.6) 4 (4.9) 4 (4.7) 
1.30 
(0.56-3.03) 
0.547 
1.65 
(0.55-4.93) 
0.372 
1.68 
(0.56-5.02) 
0.354 
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*Tested versus the reference group, which is no/non-severe MAC with no-MVD. 
HR = hazard ratio; CI = confidence interval; MAC = mitral annular calcification; MVD = mitral valve diseases including mitral stenosis (≥mild) and mitral regurgitation (≥moderate). 
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Table 6. Predictive factors for all-cause death at 1 year 
Variables Univariate analysis Variables Multivariate analysis 
HR (95% CI) p value HR (95% CI) p value 
No/Non-severe MAC + Non-MVD [Reference] No/Non-severe MAC + non-MVD [Reference] 
No/Non-severe MAC + MVD 2.89 (1.96-4.26) <0.001 No/Non-severe MAC + MVD 2.33 (1.56-3.47) <0.001 
Severe MAC + Non-MVD 0.67 (0.27-1.67) 0.386 Severe MAC + non-MVD 0.52 (0.21-1.33) 0.173 
Severe MAC + MVD 2.40 (1.38-4.17) 0.002 Severe MAC + MVD 1.97 (1.12-3.44) 0.018 
Age 1.01 (0.98-1.04) 0.439 Body mass index 0.94 (0.90-0.98) 0.004 
Female 0.77 (0.54-1.10) 0.149 NYHA class Ⅲ/Ⅳ 1.98 (1.23-3.19) 0.005 
Body mass index 0.94 (0.91-0.98) 0.004 Hypertension 0.60 (0.39-0.93) 0.022 
STS score: mortality 1.08 (1.05-1.12) <0.001 Diabetes 2.37 (1.61-3.49) <0.001 
NYHA class Ⅲ/Ⅳ 2.27 (1.42-3.63) 0.001 Prior stroke or TIA 1.44 (0.92-2.27) 0.114 
Hypertension 0.64 (0.42-0.97) 0.035 Peripheral artery disease 1.73 (1.11-2.71) 0.016 
Diabetes 2.03 (1.41-2.91) <0.001  
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Dyslipidemia 0.84 (0.59-1.20) 0.340 
CKD (eGFR<60)  1.59 (1.05-2.41) 0.029 
COPD 1.36 (0.84-2.19) 0.212 
Coronary artery disease 1.02 (0.71-1.46) 0.921 
Prior stroke or TIA 1.79 (1.15-2.79) 0.011 
Peripheral artery disease 1.80 (1.17-2.77) 0.008 
Permanent pacemaker 1.59 (0.94-2.68) 0.085 
Atrial fibrillation 1.89 (1.32-2.70) 0.001 
Hemoglobin 0.99 (0.98-0.99) 0.005 
BNP 1.00 (1.00-1.00) <0.001 
Aortic valve area 1.15 (0.57-2.31) 0.700 
LV ejection fraction 0.98 (0.97-0.99) 0.000 
AR ≥ moderate ¶  
TR ≥ moderate 4.00 (1.63-9.78) 0.002 
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Annulus area 1.00 (1.00-1.00) 0.152 
AVC calcium 1.00 (1.00-1.00) 0.076 
LVOT calcium  1.00 (1.00-1.01) 0.003 
Trans-femoral access 0.63 (0.38-1.06) 0.080 
 
All the variables were stepwise tested for entry into the multivariate model, with p value of entry of 0.10. Estimates were based on 20 multiple imputed datasets, 
combining estimates using Rubin’s rule. 
HR = hazard ratio; CI = confidence interval; MAC = mitral annular calcification; MVD = mitral valve diseases including mitral stenosis (≥mild) and mitral 
regurgitation (≥moderate); STS = Society of Thoracic Surgeons; NYHA = New York Heart Association; CKD = chronic kidney disease; COPD = chronic obstructive 
pulmonary disease; TIA = transient ischemic attack; LBBB = left bundle branch block; RBBB = right bundle branch block; LV = left ventricular; LA = left atrium; AR 
= aortic regurgitation; MR = mitral regurgitation; MS = mitral stenosis; AVC = aortic valve complex; LVOT = left ventricular outflow tract. 
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Table 7. Independent effects of severe MAC, MS, and MR on 1-year mortality  
Variables 
 Unadjusted Adjusted 
sample size Deaths (%) HR (95% CI) p-value HR (95% CI) p-value 
Non-severe MAC + Non-MVD 567 49 (8.8) [Reference]  [Reference]  
+ severe MAC 172 22 (12.8) 1.51 (0.91-2.49) 0.110 1.16 (0.69-1.96) 0.570 
+ MS 168 38 (22.8) 2.81 (1.84-4.30) <0.001 2.37 (1.53-3.66) <0.001 
+ MR 167 38 (22.8) 2.82 (1.84-4.30) <0.001 1.88 (1.20-2.94) 0.005 
+ severe MAC + MS 58 11 (19.0) 2.33 (1.21-4.48) 0.011 1.67 (0.85-3.30) 0.14 
+ severe MAC + MR 36 8 (22.2) 2.77 (1.31-5.85) 0.008 1.62 (0.73-3.56) 0.23 
+ MR + MS 20 6 (30.0) 3.87 (1.66-9.05) 0.002 1.90 (0.77-4.67) 0.16 
+ severe MAC +MS + MR 7 2 (28.6) 3.87 (0.94-15.92) 0.061 1.06 (0.23-4.93) 0.94 
 
Adjusted for body mass index, NYHA class Ⅲ/Ⅳ, hypertension, diabetes, prior stroke or TIA, peripheral artery disease. 
HR = hazard ratio; CI = confidence interval; MAC = mitral annular calcification; MVD = mitral valve diseases including mitral stenosis (≥mild) and mitral 
regurgitation (≥moderate); MS = mitral stenosis (≥mild); MR = mitral regurgitation (≥moderate). 
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FIGURE LEGENDS 
Figure 1 Grading of MAC severity by Computed Tomography 
MAC severity was qualitatively determined by the circumferential involvement of the mitral ring: mild was defined as involvement in 
less than 1/3 of the annulus; moderate between 1/3 and 1/2; and severe if the calcification was present in more than half of the 
mitral annulus circumference (1, 15). MAC = mitral annular calcification. 
 
Figure 2 Study flow chart.  
TAVR = transcatheter aortic valve replacement; CT = computed tomography; MAC = mitral annular calcification; MR = mitral 
regurgitation; MS = mitral stenosis; MVD = mitral valve disease including moderate or severe MR and mild or greater MS. 
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Figure 3 Prevalence of MVD according to the presence or absence of severe MAC.  
The prevalence of MVD significantly increased in patients with severe MAC (p<0.001). MAC = mitral annular calcification; MS = 
mitral stenosis (≥mild); MR = mitral regurgitation (≥moderate); MSR = mitral stenosis (≥mild) with regurgitation (≥moderate); MVD 
= mitral valve disease including MS and MR. 
 
Figure 4 Kaplan-Meier curves of (A) all-cause death and (B) cardiovascular death according to the severity of MAC.  
Blue lines indicate no MAC; orange lines indicate mild/moderate MAC; red lines indicate severe MAC. MAC = mitral annular 
calcification; HR = hazard risk; CI = confidence interval. 
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Figure 5 Survival curves stratified by the presence or absence of severe MAC and relevant MVD.  
The Kaplan-Meier curves show similar increased risks of (A) all-cause and (B) cardiovascular death both in patients with MVD 
regardless of presence or absence of severe MAC, whereas patients with isolated severe MAC had comparable survival compared to 
patients without severe MAC and MVD. Light blue lines indicate non-severe MAC without MVD; blue lines indicate isolated MVD; 
orange lines indicate isolated severe MAC; red lines indicate severe MAC concomitant with MVD. MAC = mitral annular calcification; 
MS = mitral stenosis (≥mild); MR = mitral regurgitation (≥moderate); MSR = mitral stenosis (≥mild) with regurgitation (≥moderate); 
MVD = mitral valve disease including MS and MR. 
 
Figure 6 Bar graph illustrating all-cause death at 1 year according to concomitant MAC, MR, and MS.  
MAC = mitral annular calcification; MR = mitral regurgitation (≥moderate); MS = mitral stenosis (≥mild); MSR = mitral stenosis 
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(≥mild) with regurgitation (≥moderate); MVD = mitral valve disease including MS and MR. 
 
Figure 7 Prevalence of MS and MR according to the severity of MAC.  
MAC = mitral annular calcification; MS = mitral stenosis; MR = mitral regurgitation.  
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Figures 
Figure 1 Grading of MAC severity by Computed Tomography 
 
 
Published in final edited form as: Eur Heart J Cardiovasc Imaging. 2019 Aug 13. pii: jez208. doi: 10.1093/ehjci/jez208 
44 
 
Figure 2 Study flow chart.  
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Figure 3 Prevalence of MVD according to the presence or absence of severe MAC.  
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Figure 4 Kaplan-Meier curves of (A) all-cause death and (B) cardiovascular death according to the severity of MAC.  
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Figure 5 Survival curves stratified by the presence or absence of severe MAC and relevant MVD.  
 
 
 
Published in final edited form as: Eur Heart J Cardiovasc Imaging. 2019 Aug 13. pii: jez208. doi: 10.1093/ehjci/jez208 
48 
 
Figure 6 Bar graph illustrating all-cause death at 1 year according to concomitant MAC, MR, and MS.  
 
 
 
Published in final edited form as: Eur Heart J Cardiovasc Imaging. 2019 Aug 13. pii: jez208. doi: 10.1093/ehjci/jez208 
49 
 
Figure 7 Prevalence of MS and MR according to the severity of MAC.  
 
